hrp0098ha2 | A novel human disorder: QSOX2 deficiency‐induced growth restriction, gastrointestinal dysmotility and immune dysfunction highlights a new mechanism of disease. | ESPE2024

A novel human disorder: QSOX2 deficiency-induced growth restriction, gastrointestinal dysmotility and immune dysfunction highlights a new mechanism of disease.

Maharaj Avinaash , Ishida Miho , Rybak Anna , Elfeky Reem , Andrews Afiya , McGuffin Liam , Hwa Vivian , Storr Helen

Background: Defects in growth hormone (GH) action account for a substantial percentage of endocrine causes of growth restriction but are frequently unrecognised due to wide clinical and biochemical variability. We report five probands from three families who present with short stature, features of atypical growth hormone insensitivity (GHI), immune dysfunction, atopic eczema, and gastrointestinal pathology associated with novel recessive variants in a new gene...

hrp0098fc5.2 | Growth and Syndromes | ESPE2024

The pathogenesis of Noonan syndrome and associated growth restriction is modulated by NOC2L, a novel interactor of LZTR1 leading to impaired p53 signalling

Maharaj Avinaash , Chatterjee Sumana , Bertola Débora , Chizo Agwu Juliana , Gaston-Massuet Carles , McGuffin Liam , Storr Helen

Background: The underlying pathogenic mechanisms governing growth restriction of Noonan syndrome (NS) remain elusive. Monoallelic inactivating LZTR1 gene variants have been implicated as a cause of NS due to hyperactivation of the canonical RAS-MAPK signalling pathway. Missense LZTR1 variants have been associated with defective ubiquitination theoretically leading to increased Ras substrate availability. Ubiquitination is implicated in growth...